上海凯来 点击免费限量礼盒 特别提示 微信公众号机制调整，请点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无 法看到我们的推送。 仪粉er们，今天是精品仪器类职位专辑 哦！ 仪器精英，热招职位 Ho t r e c r u itme n t p o siti o n s 销售经理（液体产品线） 上海-25k-40k ·12薪 任职要求： 化学、生物学、材料学等相关专业，本科及以上学历；熟悉ICP-MS液体进样相关 前处理技术和市场，十年以上仪器销售经验，五年以上团队管理经验；熟悉元素分析类用户的 市场特点，能适应出差。 中仪宇盛 销售工程师 广州、上海、贵阳、武汉-10k-15k ·12薪 任职要求： 能接受出差；有分析仪器行业相关工作经验，年龄40以内；专科及以上学历，分 析化学、化工等相关专业优先；热爱销售工作，性格开朗自信；有责任心，上进心，能承受较 大压力、有较强的团队合作精神。 明月湖实验室 复材工艺工程师 重庆-面议 任职要求： 参与产品工艺设计开发及评审，提供工艺可行性建议，优化设计方案；参与产线设 计和建设，根据产品需求设计生产工艺流程，确定产线布局；提供生产用工装、 ...

Financial giants have made a conspicuous bearish move on Thermo Fisher Scientific. Our analysis of options history for Thermo Fisher Scientific (NYSE:TMO) revealed 9 unusual trades.Delving into the details, we found 22% of traders were bullish, while 55% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $176,400, and 7 were calls, valued at $558,411.Projected Price TargetsBased on the trading activity, it appears that the significant investors are aiming for a price t ...

Brown Brothers Harriman, an investment management company, released its Q3 2025 investor letter for the BBH Select Series - Mid Cap Fund. A copy of the same can be downloaded here. In the quarter, the fund decreased by -0.9% on a total return basis compared to the Russell Midcap Index’s 5.3% return. The Fund has decreased by a total return of -1.8%, YTD, compared to 10.4% for the Index. The third quarter experienced a boost in the low-quality rally that started late last year and gained momentum throughout ...

1.12亿元！苏州大学一个月内采购大批仪器设备 2025.7 1.24亿元！双一流苏州大学采购大批仪器 2025.9 9237万元！中国最美大学苏州大学采购大批仪器 2025.8 1.05亿元！苏州大学采购大批仪器 2025.8 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我 们的推送。 近日， 苏州大学发布 1 7 项仪器设备采购意向，预算总额达 8 1 4 3万 元，涉及实时无标记细胞 功能分析仪 、X波段连续波电子顺磁共振谱仪、高通量荧光成像系统、6 0 0MHz固体宽腔核磁 共振波谱仪 等，预计采购时间为2 0 2 5 年 8~1 2 月。 相关采购： 1.24亿元！苏州大学发布25项仪器设备采购意向 2025.7 点击免费限量礼盒 摘要 ： 近日，苏州大学发布多批政府采购意向，仪器信息网特对其中的仪器设备品目进行梳理，统计出 17项仪器设备采购意向，预算总额达8143万元 详细采购清单： 苏州大学 202 5 年 8~12 月仪器设备采购 意向汇总表 | 采购项目 | 需求概况 | 预算 | 采购 | | --- | --- | --- | ...

Core Points - Nanalysis Scientific Corp. plans to complete a non-brokered private placement of up to 16,666,667 units at a price of $0.15 per unit, aiming for gross proceeds of up to $2,500,000, which will be used for debt reduction [1][4] Group 1: Offering Details - Each unit will consist of one common share and one-half of a common share purchase warrant, with each whole warrant allowing the purchase of one share at an exercise price of $0.20, valid for two years from the closing date [2] - The warrants include an acceleration provision, allowing the company to accelerate the expiry date if the closing price of shares exceeds $0.30 for 10 consecutive trading days [3] - The offering is subject to acceptance by the TSX Venture Exchange and may close in multiple tranches, with the initial closing expected around December 15, 2025 [4] Group 2: Company Overview - Nanalysis Scientific Corp. develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers used in various industries including pharma, biotech, energy, food, materials, and security [6] - The company operates a services division that maintains its products and third-party imaging equipment, supported by a $160 million long-term contract with the Canadian Air Transport Security Authority to maintain security scanners at over 80 Canadian airports [6]

Company Overview - Agilent Technologies, Inc. has a market cap of $42.3 billion and provides application-focused solutions for life sciences, diagnostics, and applied chemical markets globally [1] - The company operates through three segments: Life Sciences and Applied Markets; Diagnostics and Genomics; and Agilent CrossLab, offering a wide range of instruments, consumables, software, and laboratory services [1] Stock Performance - Agilent's shares have decreased by 6.9% from its 52-week high of $160.27, but have increased by 19.2% over the past three months, outperforming The Health Care Select Sector SPDR Fund's (XLV) 13.3% gain during the same period [3] - Over the past 52 weeks, Agilent's stock has risen by 7.2%, surpassing XLV's 5.6% return, but is up only 11.1% year-to-date, lagging behind XLV's 12.7% return [4] Financial Results - Following its Q4 2025 results, Agilent's shares rose by 2.3%, with revenue of $1.86 billion exceeding estimates and adjusted EPS of $1.59 meeting expectations [5] - Key segments showed strong performance, with Life Sciences and Diagnostics revenue at $755 million and a 7% increase in CrossLab revenue to $775 million [5] - The company projects fiscal 2026 revenue between $7.3 billion and $7.4 billion, with adjusted EPS expected to be between $5.86 and $6 [5] Competitive Landscape - Despite Agilent's positive outlook, rival Eli Lilly and Company has outperformed, with LLY stock surging 33.9% year-to-date and 27.1% over the past 52 weeks [6] - Analysts maintain a moderately optimistic view on Agilent, with a consensus rating of "Moderate Buy" from 17 analysts and a mean price target of $169.62, indicating a 13.6% premium to current levels [6]

It has been about a month since the last earnings report for Bruker (BRKR) . Shares have added about 17.1% in that time frame, outperforming the S&P 500.But investors have to be wondering, will the recent positive trend continue leading up to its next earnings release, or is Bruker due for a pullback? Well, first let's take a quick look at its most recent earnings report in order to get a better handle on the recent catalysts for Bruker Corporation before we dive into how investors and analysts have reacted ...

Core Insights - The "Domestic Mass Spectrometry Instrument Innovation Development and Application Forum" successfully convened, gathering various stakeholders from industry, academia, and research to discuss cutting-edge mass spectrometry technology and its applications in the semiconductor industry [2][14]. Group 1: Forum Overview - The forum was organized by Suzhou Laboratory and co-hosted by several institutions, focusing on the macro planning and ecological construction of domestic scientific instruments and their applications in the semiconductor sector [2]. - Discussions included the "National Instrument High Quality" certification system aimed at enhancing the quality of domestic instruments, as well as the "Domestic Instrument Take-off Action" initiative presented by Beijing Xinlifang Technology Development Co., Ltd. [2]. Group 2: Technical Developments - Reports from various organizations highlighted advancements in whole machine development and key technology breakthroughs, including an analysis of the current state and development strategy of domestic mass spectrometers by Beijing Huairou Science City Mass Spectrometry Technology Research Institute [14]. - Key components and foundational technology autonomy were focal points, with presentations on the development of quadrupole mass spectrometer components and the progress of domestic molecular pump technology [14]. Group 3: Semiconductor Applications - Specific applications of domestic ICP-MS/MS in silicon wafer and wet electronic chemical detection were showcased, along with discussions on the practical challenges and applications of mass spectrometry technology in semiconductor testing and result traceability [15]. - The forum also addressed supporting technologies for gas pollutant detection and ultra-pure reagents, outlining a complete technical chain to ensure semiconductor yield [15]. Group 4: Industry Collaboration - The forum facilitated a high-density agenda that showcased the progress of domestic mass spectrometry technology across components, whole machines, and system applications, establishing an efficient platform for cross-domain collaboration [15]. - The successful hosting of the forum marks a significant step towards overcoming high-end scientific instrument challenges and enhancing the self-sufficiency of the semiconductor industry chain [15].

Core Insights - Agilent Technologies reported revenue of $1.86 billion for Q4 2025, exceeding revenue guidance and showing a growth of 9.4% reported and 7.2% core compared to Q4 2024 [1] - The company's GAAP net income for Q4 2025 was $434 million, or $1.53 per share, an increase from $351 million, or $1.22 per share, in Q4 2024 [1] - Non-GAAP net income for Q4 2025 was $452 million, or $1.59 per share [1]

Core Insights - Madison Mid Cap Fund's Class I returned 1.9% in Q3 2025, underperforming the Russell Midcap Index which increased by 5.3% [1] - The Information Technology sector led performance in both the quarter and year-to-date [1] Company Performance - MKS Instruments, Inc. (NASDAQ:MKSI) reported a one-month return of -3.11% but gained 20.51% over the last 52 weeks, closing at $138.49 per share with a market capitalization of $9.302 billion on November 20, 2025 [2] - MKS Instruments, Inc. achieved revenue of $988 million in Q3 2025, reflecting a 2% sequential increase and a 10% year-over-year growth [4] Investment Sentiment - MKS Instruments, Inc. was highlighted as a strong performer in the technology sector during Q3, benefiting from an improving semiconductor cycle and positive investor sentiment [3] - The number of hedge funds holding MKS Instruments, Inc. increased from 32 to 33 in the second quarter of 2025 [4]